MYO19

Across TCGA pan-cancer cohorts, MYO19 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated MYO19 data layer compared with 27 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher MYO19 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated MYO19 expression acts as an unfavorable survival marker.

PDAC, LUAD, and GBM are the cancer types where MYO19 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	All	0.822	1.000	.004	27	view →
LUAD	DFS	Tertile	All	0.446	0.780	.004	16	view →
GBM	OS	Median	All	0.238	0.485	.006	10	view →
LSCC	OS	Tertile	III,IV	0.444	0.986	.013	8	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

MYO19–PDAC (OS)

Open the PDAC breakdown →